Serum Concentrations of F 2-Isoprostanes and 4-Hydroxynonenal in Hemodialysis Patients in Relation to Inflammation and Renal Anemia

Biomarker Insights

Volumn 3, Issue , 2008, Pages

  Wiswedel, Ingrid ^a   Peter, Daniela ^a   Gardemann, Andreas ^a   Carluccio, Francesco ^d   Hampl, Hannelore ^c   Siems, Werner ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Research Institute of Physiotherapy and Gerontology   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d CNR   (Italy)

Author keywords

4 hydroxynonenal; C reactive protein; end stage renal disease (ESRD); F2 isoprostanes; hemodialysis patients; renal anemia

Indexed keywords

EID: 84874511370     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMI.S363     Document Type: Article

References (69)

1. Basu S. 2004. Isoprostanes: Novel bioactive products of lipid peroxidation. Free Radic. Res., 38: 105–22.
2. Beauchamp M.H., Martinez-Bermudez A.K., Gobeil F. et al. 2001. Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy. J. Appl. Physiol., 90: 2279–99.
3. Bergstrom J., Lindhol B., Lacson E. et al. 2000. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Seminars Dialysis, 13: 163–75.
4. Blasig I.E., Grune T., Schoenheit K. et al. 1995. 4-Hydroxynonenal, a novel indicator of lipid peroxidation for reperfusion injury of the myocardium. Am. J. Physiol., 269(Heart Circ. Physiol. 38): H14–H22.
5. Canaud B., Cristol J., Morena M. et al. 1999. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif., 17: 99–106.
6. Cavdar C., Camsari T., Semin I.,et al. 1997. Lipid peroxidation and antioxidant activity in chronic hemodialysis patients with recombinant human erythropoietin. Scand J. Urol. Nephrol., 31: 371–75.
7. Ceballos-Picot I., Witko-Sarsat V., Merad-Boudia M. et al. 1996. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic. Biol. Med., 21: 845–53.
8. Coskun C., Kural A., Doventas Y. et al. 2007. Hemodialysis and protein oxidation products. Ann. N. Y. Acad. Sci., 1100: 404–8.
9. Danielski M., Ikizler T.A., McMonagle E. et al. 2003. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am. J. Kidney Dis., 42: 286–94.
10. Delmas Beauvieux M.C., Combe C., and Peuchant E. 1995. Evaluation of red blood cell lipid peroxidation in hemodialyzed patients during erythropoietin therapy supplemented or not with iron. Nephron, 31: 406–10.
11. Dogra G., Ward N., Croft K.D. et al. 2001. Oxidant stress in nephrotic syndrome: comparison of F(2)-isoprostanes and plasma antioxidant potential. Nephrol. Dial. Transplant., 16: 1626–30.
12. Esterbauer H., Cheeseman K.H., Dianzani M.U. et al. 1982. Separation and characterization of the aldehydic products of lipid peroxidation stimulated by ADP-Fe2+ in rat liver microsomes. J. Biochem., 208: 129–40.
13. Esterbauer H., Schaur R.J., and Zollner H. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med., 11: 81–128.
14. Ferraro B., Galli F., Frei B. et al. 2003. Peroxynitrite-induced oxidation of plasma lipids is enhanced in stable hemodialysis patients. Kidney Int., 63: 2207–13.
15. Foley R.N. 1995. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J. Am. Soc. Nephrol., 5: 2024–31.
16. 2 Integrin-dependent neutrophil adhesion induced by minimally modified low-density lipoproteins is mainly mediated by F2-isoprostanes. Circulation, 106: 2434–41.
17. Fukunaga M., Makita M., Roberts L.J. et al. 1993. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am. J. Physiol., 264: 1619–24.
18. Galle J., Seibold S., and Wanner C. 2003. Inflammation in uremic patients: What is the link? Kidney Blood Press. Res., 26: 65–75.
19. Grützmeier S., and von Schenck H. 1989. Four immunochemical methods for measuring C-reactive protein in plasma compared. Clin. Chem., 35: 461–63.
20. Grune T., Siems W.G., Zollner H., and Esterbauer H. 1994. Metabolism of 4-hydroxynonenal, a cytotoxic lipid peroxidation product, in Ehrlich mouse ascites cells at different proliferation stages. Cancer Res., 54: 5231–35.
21. Handelman G.J., Walter M.F., Adhikarla R. et al. 2001. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int., 59: 1960–66.
22. Ikizler T.A., Morrow J.D., Roberts L.J. et al. 2002. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin. Nephrol., 58: 190–97.
23. Kalantar-Zadeh K., Brennan M.L., and Hazen S.L. 2006. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am. J. Kidney Dis., 48: 59–68.
24. Kim K.M., Jung B.H., Paeng et al. 2004. Alteration of F2-isoprostanes before and after hemodialysis in end-stage renal disease patients. Prostaglandins, Leukot. Essent. Fatty Acids, 70: 475–78.
25. 2 as a useful clinical biomarker of oxidative stress in ESRD patients. Blood Purif., 20: 537–42.
26. Loughrey C.M., Young I.S., Lightbody J.H. et al. 1994. Oxidative stress in hemodialysis. Q. J. Med., 87: 679–83.
27. Ludat K., Sommerburg O., Grune T. et al. 2000. Oxidation parameters in complete correction of renal anemia. Clin. Nephrol., 53(1): S30–5.
28. Montuschi P., Collins J.V., Ciabattoni G. et al. 2000. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med., 162: 1175–77.
29. Montuschi P., Barnes P.J., and Roberts L.J. 2004. Isoprostanes: markers and mediators of oxidative stress. FASEB J., 18: 1791–800.
30. Morena M., Delbosc S., Dupuy A.M. et al. 2005. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int., 9: 37–46.
31. Morrow J.D., Zackert W.E., van der Ende D.S. et al. 2002. Qantification of isoprostanes as indicators of oxidant stress in vivo. In: Handbook of Antioxidants, 2nd edition (Cadenas E., and Packer L., eds) Marcel Dekker, Inc. New York, Basel, 57–74.
32. Pai A.B., Boyd A.V., McQuade C.R. et al. 2007. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy, 27: 343–50.
33. Palleschi S., De Angelis S., Diana L. et al. 2007. Reliability of oxidative stress biomarkers in hemodialysis patients: a comparative study. Clin. Chem. Lab. Med., 45: 1211–18.
34. Patrono C., and FitzGerald G.A. 1997. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler. Thromb. Vasc. Biol., 17: 2309–15.
35. Peuchant E., Delmas-Beauvieux M.C., Dubourg L. et al. 1997. Antioxidant effects of a supplemented very low protein diet in chronic renal failure. Free Radic. Biol. Med., 22: 313–20.
36. Piroddi M., Depunzio I., Calabrese V. et al. 2007. Oxidatively-modified and glycated proteins as candidate pro-inflammatory toxins in uremia and dialysis patients. Amino Acids, 32: 573–92.
37. Ruef J., Moser M., Bode C. et al. 2001. 4-Hydroxynonenal induces apoptosis, NF-KB-activation and formation of 8-isoprostane in vascular smooth muscle cells. Basic Res. Cardiol., 96: 143–50.
38. Rutkowski P., Slominska E.M., Szolkiewicz M. et al. 2007. Relationship between uremic toxins and oxidative stress in patients with chronic renal failure. Scand J. Urol. Nephrol., 41: 243–8.
39. Salomon R.G., Batyreva E., Kaur K. et al. 2000. Isolevuglandin-protein adducts in humans: products of free radical-induced lipid oxidation through the isoprostane pathway. Biochim. Biophys. Acta., 1485: 225–35.
40. Samoulidou E., Grapsa E., Kakavas I. et al. 2003. Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis. Int. Urol. Nephrol., 35: 393–97.
41. Samoulidou E., Grapsa E., Karpouza A. et al. 2007. Reactive oxygen metabolites: a link between oxidative stress and inflammation in patients on hemodialysis. Blood Purif., 25: 175–78.
42. Scholz H., Yndestad A., Damas J.K. et al. 2003. 8-isoprostane increases expression of interleukin-8 in human macrophages through activation of mitogen-activated protein kinases. Cardiovasc. Res., 59: 945–54.
43. +-ATPase. Free Radic. Biol. Med., 20: 215–23.
44. Siems W., Quast S., Carluccio F. et al. 2002a. Oxidative stress in chronic renal failure as a cardiovascular risk factor. Clin. Nephrol., 58(1): 12–19.
45. Siems W., Carluccio F., Grune T. et al. 2002b. Elevated serum concentration of cardiotoxic lipid peroxidation products in chronic renal failure in relation to severity of renal anemia. Clin. Nephrol., 58(1): 20–5.
46. Siems W., Quast S., Carluccio F. et al. 2003. Oxidative stress in cardiorenal anemia syndrome: correlations and therapeutic possibilities. Clin. Nephrol., 60: 22–30.
47. Siems W., Carluccio F., Radenkovic S., Grune T., and Hampl H. 2005. Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment. Kidney Blood Press. Res., 28: 295–301.
48. Silverberg D.S., Wexler D., Blum M. et al. 2000. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiology (JACC), 35: 1737–44.
49. Silverberg D.S., Wexler D., Blum M. et al. 2003. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin. Nephrol., 60: 93–102.
50. Silverberg D.S., Wexler D., and Iaina A. 2004a. The role of anemia in congestive heart failure and chronic kidney insufficiency: the cardiorenal anemia syndrome. Perspect. Biol. Med., 47: 575–89.
51. Silverberg D.S., Wexler D., Blum M. et al. 2004b. The interaction between heart failure, renal failure and anemia–the cardio-renal anemia syndrome. Blood Purif., 22: 277–84.
52. Sommerburg O., Grune T., Klee S. et al. 1993. Formation of 4-hydroxynonenal and further aldehydic mediators of inflammation during bromotrichloromethane treatment of rat liver cells. Mediators Inflammation, 2: 27–31.
53. Sommerburg O., Grune T., Hampl H. et al. 1998. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients. Nephrol. Dial. Transplant., 13: 2583–87.
54. Spittle M.A., Hoenich N.A., Handelman G.J. et al. 2001. Oxidative stress and inflammation in hemodialysis patients. Am. J. Kidney Dis., 38: 1408–13.
55. Stenvinkel P., and Alvestrand A. 2002. Inflammation in end-stage renal disease: sources, consequences, and therapy. Seminars Dialysis, 15: 329–37.
56. 2α in the rat. Evidence for interaction with thromboxane A2 receptors. J. Clin. Invest., 90: 136–41.
57. Thaunat G., Beaumont C., Chatenoud L. et al. 2005. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation, 80: 1212–19.
58. Trachtman H., Wilson D., and Rao P.S. 1992. The role of oxygen-free radicals in the development of chronic renal failure. Life Sci., 50: 1877–83.
59. Tsirpanlis G. 2005. The pattern of inflammation and a potential new clinical meaning and usefulness of C-reactive protein in end-stage renal failure patients. Kidney Blood Press. Res., 28: 55–61.
60. Uchida K., Shiraishi M., Naito Y. et al. 1999. Activation of stress signaling pathway by the end product of lipid peroxidation. 4-hydroxynonenal is a potential inducer of intracellular peroxide production. J. Biol. Chem., 274: 2234–42.
61. Vollenbroeker B., Koch J.H., Fobker M., Suwelack B., Hohage H., and Muller U. 2005. Determination of cyclosporine and its metabolites in blood via HPLC-MS and correlation to clinically important parameters. Transplant. Proc., 37: 1741–44.
62. 2-isoprostane analysis in plasma and urine with high-performance liquid chromatography and gas chromatography/mass spectroscopy. Anal. Biochem., 280: 73–9.
63. Wanner C., and Metzger T. 2002. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol. Dial. Transplant., 17(suppl 8): 29–32.
64. Westhuyzen J., Adams C.E., and Fleming S.J. 1995. Evidence for oxidative stress during in vitro dialysis. Nephron, 70: 49–54.
65. 2-isoprostane concentrations in humans. Free Radic. Biol. Med., 37: 411–21.
66. 2-Isoprostanes as biomarkers of lipid peroxidation in patients with chronic renal failure. Biofactors, 24: 201–8.
67. Wratten M.L., Galaris D., Tetta C. et al. 2002. Evolution of oxidative stress and inflammation during hemodialysis and their contribution to cardiovascular disease. Antioxidants Redox Signaling, 4: 935–44.
68. Yeun J.Y., and Kaysen G.A. 2000. C-reactive protein, oxidative stress, homocysteine, and troponine as inflammatory and metabolic predictors of atherosclerosis in ESRD. Curr. Opin. Nephrol. Hypertens., 9: 621–30.
69. Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 69: 89–95.